Formoterol in patients with chronic obstructive pulmonary disease

A randomized, controlled, 3-month trial

R. Aalbers, J. Ayres, V. Backer, M. Decramer, P. A. Lier, P. Magyar, J. Malolepszy, R. Ruffin, G. W. Sybrecht

Research output: Contribution to journalArticle

130 Citations (Scopus)

Abstract

The aim of this study was to investigate formoterol, an inhaled long-acting β2-agonist, in patients with chronic obstructive pulmonary disease (COPD). Six-hundred and ninety-two COPD patients, mean baseline forced expiratory volume in one second (FEV1) 54%, FEV1/forced vital capacity 75% of predicted, reversibility 6.4% pred, were treated with formoterol (4.5, 9 or 18 μg b.i.d.) or placebo via Turbuhaler® for 12 weeks. Symptoms were recorded daily. Spirometry and the incremental shuttle walking test (SWT) were performed at clinic visits. Compared with placebo, 18 μg b.i.d. formoterol reduced the mean total symptom score by 13% and increased the percentage of nights without awakenings by 15%. Formoterol (9 and 18 μg b.i.d.) significantly reduced symptom scores for breathlessness (-7% and -9%, respectively) and chest tightness (-11% and -8%, respectively), reduced the need for rescue medication (-25% and -18%, respectively), and increased symptom-free days (71% and 86%, respectively). FEV1 improved significantly after all three doses of formoterol (versus placebo). No differences were found between groups in SWT walking distance. No unexpected adverse events were seen. In conclusion, 9 and 18 μg b.i.d. formoterol reduced symptoms and increased the number of symptom-free days in a dose-dependent manner in chronic obstructive pulmonary disease patients. Formoterol improved lung function at a dose of 4.5 μg b.i.d. and higher.

Original languageEnglish
Pages (from-to)936-943
Number of pages8
JournalEuropean Respiratory Journal
Volume19
Issue number5
DOIs
Publication statusPublished - 2002

Fingerprint

Chronic Obstructive Pulmonary Disease
Walking
Placebos
Spirometry
Vital Capacity
Forced Expiratory Volume
Ambulatory Care
Formoterol Fumarate
Dyspnea
Thorax
Lung

Keywords

  • Bronchodilation
  • Chronic obstructive pulmonary disease
  • Formoterol

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

Formoterol in patients with chronic obstructive pulmonary disease : A randomized, controlled, 3-month trial. / Aalbers, R.; Ayres, J.; Backer, V.; Decramer, M.; Lier, P. A.; Magyar, P.; Malolepszy, J.; Ruffin, R.; Sybrecht, G. W.

In: European Respiratory Journal, Vol. 19, No. 5, 2002, p. 936-943.

Research output: Contribution to journalArticle

Aalbers, R, Ayres, J, Backer, V, Decramer, M, Lier, PA, Magyar, P, Malolepszy, J, Ruffin, R & Sybrecht, GW 2002, 'Formoterol in patients with chronic obstructive pulmonary disease: A randomized, controlled, 3-month trial', European Respiratory Journal, vol. 19, no. 5, pp. 936-943. https://doi.org/10.1183/09031936.02.00240902
Aalbers, R. ; Ayres, J. ; Backer, V. ; Decramer, M. ; Lier, P. A. ; Magyar, P. ; Malolepszy, J. ; Ruffin, R. ; Sybrecht, G. W. / Formoterol in patients with chronic obstructive pulmonary disease : A randomized, controlled, 3-month trial. In: European Respiratory Journal. 2002 ; Vol. 19, No. 5. pp. 936-943.
@article{cd204ed0a3fe4a268427ec3575d419b3,
title = "Formoterol in patients with chronic obstructive pulmonary disease: A randomized, controlled, 3-month trial",
abstract = "The aim of this study was to investigate formoterol, an inhaled long-acting β2-agonist, in patients with chronic obstructive pulmonary disease (COPD). Six-hundred and ninety-two COPD patients, mean baseline forced expiratory volume in one second (FEV1) 54{\%}, FEV1/forced vital capacity 75{\%} of predicted, reversibility 6.4{\%} pred, were treated with formoterol (4.5, 9 or 18 μg b.i.d.) or placebo via Turbuhaler{\circledR} for 12 weeks. Symptoms were recorded daily. Spirometry and the incremental shuttle walking test (SWT) were performed at clinic visits. Compared with placebo, 18 μg b.i.d. formoterol reduced the mean total symptom score by 13{\%} and increased the percentage of nights without awakenings by 15{\%}. Formoterol (9 and 18 μg b.i.d.) significantly reduced symptom scores for breathlessness (-7{\%} and -9{\%}, respectively) and chest tightness (-11{\%} and -8{\%}, respectively), reduced the need for rescue medication (-25{\%} and -18{\%}, respectively), and increased symptom-free days (71{\%} and 86{\%}, respectively). FEV1 improved significantly after all three doses of formoterol (versus placebo). No differences were found between groups in SWT walking distance. No unexpected adverse events were seen. In conclusion, 9 and 18 μg b.i.d. formoterol reduced symptoms and increased the number of symptom-free days in a dose-dependent manner in chronic obstructive pulmonary disease patients. Formoterol improved lung function at a dose of 4.5 μg b.i.d. and higher.",
keywords = "Bronchodilation, Chronic obstructive pulmonary disease, Formoterol",
author = "R. Aalbers and J. Ayres and V. Backer and M. Decramer and Lier, {P. A.} and P. Magyar and J. Malolepszy and R. Ruffin and Sybrecht, {G. W.}",
year = "2002",
doi = "10.1183/09031936.02.00240902",
language = "English",
volume = "19",
pages = "936--943",
journal = "European Respiratory Journal",
issn = "0903-1936",
publisher = "European Respiratory Society",
number = "5",

}

TY - JOUR

T1 - Formoterol in patients with chronic obstructive pulmonary disease

T2 - A randomized, controlled, 3-month trial

AU - Aalbers, R.

AU - Ayres, J.

AU - Backer, V.

AU - Decramer, M.

AU - Lier, P. A.

AU - Magyar, P.

AU - Malolepszy, J.

AU - Ruffin, R.

AU - Sybrecht, G. W.

PY - 2002

Y1 - 2002

N2 - The aim of this study was to investigate formoterol, an inhaled long-acting β2-agonist, in patients with chronic obstructive pulmonary disease (COPD). Six-hundred and ninety-two COPD patients, mean baseline forced expiratory volume in one second (FEV1) 54%, FEV1/forced vital capacity 75% of predicted, reversibility 6.4% pred, were treated with formoterol (4.5, 9 or 18 μg b.i.d.) or placebo via Turbuhaler® for 12 weeks. Symptoms were recorded daily. Spirometry and the incremental shuttle walking test (SWT) were performed at clinic visits. Compared with placebo, 18 μg b.i.d. formoterol reduced the mean total symptom score by 13% and increased the percentage of nights without awakenings by 15%. Formoterol (9 and 18 μg b.i.d.) significantly reduced symptom scores for breathlessness (-7% and -9%, respectively) and chest tightness (-11% and -8%, respectively), reduced the need for rescue medication (-25% and -18%, respectively), and increased symptom-free days (71% and 86%, respectively). FEV1 improved significantly after all three doses of formoterol (versus placebo). No differences were found between groups in SWT walking distance. No unexpected adverse events were seen. In conclusion, 9 and 18 μg b.i.d. formoterol reduced symptoms and increased the number of symptom-free days in a dose-dependent manner in chronic obstructive pulmonary disease patients. Formoterol improved lung function at a dose of 4.5 μg b.i.d. and higher.

AB - The aim of this study was to investigate formoterol, an inhaled long-acting β2-agonist, in patients with chronic obstructive pulmonary disease (COPD). Six-hundred and ninety-two COPD patients, mean baseline forced expiratory volume in one second (FEV1) 54%, FEV1/forced vital capacity 75% of predicted, reversibility 6.4% pred, were treated with formoterol (4.5, 9 or 18 μg b.i.d.) or placebo via Turbuhaler® for 12 weeks. Symptoms were recorded daily. Spirometry and the incremental shuttle walking test (SWT) were performed at clinic visits. Compared with placebo, 18 μg b.i.d. formoterol reduced the mean total symptom score by 13% and increased the percentage of nights without awakenings by 15%. Formoterol (9 and 18 μg b.i.d.) significantly reduced symptom scores for breathlessness (-7% and -9%, respectively) and chest tightness (-11% and -8%, respectively), reduced the need for rescue medication (-25% and -18%, respectively), and increased symptom-free days (71% and 86%, respectively). FEV1 improved significantly after all three doses of formoterol (versus placebo). No differences were found between groups in SWT walking distance. No unexpected adverse events were seen. In conclusion, 9 and 18 μg b.i.d. formoterol reduced symptoms and increased the number of symptom-free days in a dose-dependent manner in chronic obstructive pulmonary disease patients. Formoterol improved lung function at a dose of 4.5 μg b.i.d. and higher.

KW - Bronchodilation

KW - Chronic obstructive pulmonary disease

KW - Formoterol

UR - http://www.scopus.com/inward/record.url?scp=0036014549&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036014549&partnerID=8YFLogxK

U2 - 10.1183/09031936.02.00240902

DO - 10.1183/09031936.02.00240902

M3 - Article

VL - 19

SP - 936

EP - 943

JO - European Respiratory Journal

JF - European Respiratory Journal

SN - 0903-1936

IS - 5

ER -